JP7626698B2 - 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 - Google Patents

操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 Download PDF

Info

Publication number
JP7626698B2
JP7626698B2 JP2021517801A JP2021517801A JP7626698B2 JP 7626698 B2 JP7626698 B2 JP 7626698B2 JP 2021517801 A JP2021517801 A JP 2021517801A JP 2021517801 A JP2021517801 A JP 2021517801A JP 7626698 B2 JP7626698 B2 JP 7626698B2
Authority
JP
Japan
Prior art keywords
seq
antibody
binding
cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022503961A (ja
JP2022503961A5 (https=
JPWO2020065409A5 (https=
Inventor
ワン，ジエイー
ウー，イー
Original Assignee
リビジェン バイオファーマ ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リビジェン バイオファーマ ホールディングス リミテッド filed Critical リビジェン バイオファーマ ホールディングス リミテッド
Publication of JP2022503961A publication Critical patent/JP2022503961A/ja
Publication of JP2022503961A5 publication Critical patent/JP2022503961A5/ja
Publication of JPWO2020065409A5 publication Critical patent/JPWO2020065409A5/ja
Application granted granted Critical
Publication of JP7626698B2 publication Critical patent/JP7626698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021517801A 2018-09-28 2019-09-27 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 Active JP7626698B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018010828 2018-09-28
CNPCT/CN2018/010828 2018-09-28
PCT/IB2019/001135 WO2020065409A2 (en) 2018-09-28 2019-09-27 Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof

Publications (4)

Publication Number Publication Date
JP2022503961A JP2022503961A (ja) 2022-01-12
JP2022503961A5 JP2022503961A5 (https=) 2022-10-04
JPWO2020065409A5 JPWO2020065409A5 (https=) 2022-10-04
JP7626698B2 true JP7626698B2 (ja) 2025-02-04

Family

ID=69950020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517801A Active JP7626698B2 (ja) 2018-09-28 2019-09-27 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途

Country Status (4)

Country Link
JP (1) JP7626698B2 (https=)
AU (1) AU2019349874A1 (https=)
CA (1) CA3114567A1 (https=)
WO (1) WO2020065409A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512572B (zh) 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
CR20230119A (es) * 2020-08-07 2023-05-16 Genentech Inc Proteínas de fusión del ligando para flt3 y métodos de uso
JP2024500945A (ja) * 2020-12-23 2024-01-10 マクファーレン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッド ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法
WO2024126289A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126294A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515469A (ja) 2003-12-22 2007-06-14 ファイザー・プロダクツ・インク Ｃｄ４０抗体製剤および方法
JP2009022289A (ja) 2003-12-25 2009-02-05 Kyowa Hakko Kirin Co Ltd 抗ｃｄ４０抗体の変異体
JP2010514460A (ja) 2007-01-23 2010-05-06 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
JP2014531201A (ja) 2011-09-05 2014-11-27 アリゲーター・バイオサイエンス・アーベー 抗ｃｄ４０抗体、使用、および方法
US20170253659A1 (en) 2016-03-04 2017-09-07 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
JP2018515072A (ja) 2015-05-04 2018-06-14 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質
JP2018518491A (ja) 2015-06-12 2018-07-12 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515469A (ja) 2003-12-22 2007-06-14 ファイザー・プロダクツ・インク Ｃｄ４０抗体製剤および方法
JP2009022289A (ja) 2003-12-25 2009-02-05 Kyowa Hakko Kirin Co Ltd 抗ｃｄ４０抗体の変異体
JP2010514460A (ja) 2007-01-23 2010-05-06 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
JP2014531201A (ja) 2011-09-05 2014-11-27 アリゲーター・バイオサイエンス・アーベー 抗ｃｄ４０抗体、使用、および方法
JP2018515072A (ja) 2015-05-04 2018-06-14 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質
JP2018518491A (ja) 2015-06-12 2018-07-12 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたｃｄ４０に対する抗体
US20170253659A1 (en) 2016-03-04 2017-09-07 The Rockefeller University Antibodies to cd40 with enhanced agonist activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Science，2011年，Vol. 333, No. 6045，pp. 1030-1034，doi: 10.1126/science.1206954

Also Published As

Publication number Publication date
CA3114567A1 (en) 2020-04-02
WO2020065409A8 (en) 2021-06-17
AU2019349874A1 (en) 2021-04-29
JP2022503961A (ja) 2022-01-12
WO2020065409A3 (en) 2020-05-07
WO2020065409A2 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP7626698B2 (ja) 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
JP7682102B2 (ja) ヒト化抗ｃｄ１３７抗体およびその使用
US20220372155A1 (en) Anti-cd40 binding molecules and bi-specific antibodies comprising such
US12024560B2 (en) Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
CN111542342B (zh) 抗cd137抗体及其用途
WO2020069382A1 (en) Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
US20220081487A1 (en) Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
US20240218069A1 (en) Bi-specific antibodies comprising anti-b7h3 binding molecules
US20230406950A1 (en) Bi-specific antibodies comprising anti-cd137 binding molecules
US11976123B2 (en) Anti-CD40 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250123

R150 Certificate of patent or registration of utility model

Ref document number: 7626698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150